HIGHLIGHTS
- who: Seok-Mo Kim et al. from the Department of Surgery, Cancer Center, Severance Hospital, Institute of Refractory Cancer, Yonsei University College of Medicine, Inc, Canal Street, th Floor, Lowell, MA, USA have published the paper: Potential Therapeutic Agents against Paclitaxelu2014And Sorafenib-Resistant Papillary Thyroid Carcinoma, in the Journal: (JOURNAL) of 15/Oct/2021
- what: The authors proposed a new clinical approach for the treatment of therapy-refractory PTC. This study identified the sarco/endoplasmic_reticulum calcium ATPase (SERCA) as being dominantly expressed in a patient-derived xenograft tumor model developed with antineoplastic-resistant PTC cells . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.